• Exchange: OTC US
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Spectral Diagnostics Inc

+ Add to Watchlist


0.3110 USD 0.0415 15.40%

As of 20:10:04 ET on 12/19/2014.

Snapshot for Spectral Diagnostics Inc (DIAGF)

Open: 0.3150 Day's Range: 0.3000 - 0.3150 Volume: 42,903
Previous Close: 0.2695 52wk Range: 0.2092 - 0.6100 1-Yr Rtn: -39.02%

Stock Chart for DIAGF

No chart data available.
  • DIAGF:US 0.3110
  • 1D
  • 1M
  • 1Y
Interactive DIAGF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DIAGF

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (CAD) (ttm) -
Est. EPS (CAD) (12/2014) -0.0800
Est. PEG Ratio -
Market Cap (M USD) 55.90
Shares Outstanding (M) 179.74
30 Day Average Volume 22,521
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 3.0000
Dividend Ex-Date 06/20/2001
5 Year Dividend Growth -
Next Earnings Announcement 03/27/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DIAGF

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for DIAGF

Spectral Diagnostics is inPhase III, seeking FDA approval for its theranostics product for the treatment of severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay, Spectral's EUPHRATES trial is a theranostics trial in the area of sepsis.

Paul M WalkerPresident/CEOAnthony BusinskasExec VP/CFO/Secy
Debra FosterVP:Clinical Development
More Company Profile & Key Executives for DIAGF

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil